|Name||PRICE||MARKET CAPITALIZATION||PRICE TO EARNINGS RATIO||DIVIDEND YIELD||SYMBOL||EXCHANGE||PRICE PERCENT DIFFERENCE||YEAR TO DATE PRICE PERCENT DIFFERENCE||5 YEAR CHART||1 YEAR CHART|
KemPharm Inc [KMPH]
$1.67 0.18 (12.08%)
Market Cap 40 Million
KemPharm Inc is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that believe will be improved versions of widely prescribed, approved drugs. The company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. Its LAT platform technology discovers and develops prodrugs that improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability, and safety. KemPharm's two lead product candidates are KP415, ER d-threo-methylphenidate product candidate for the treatment of ADHD, and KP201/IR, APAP-free, single-entity, benzhydrocodone hydrochloride IR abuse-deterrent product candidate designed for the treatment of acute pain.
EPS -0.46 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Pay Date --